Oncolytics Biotech Launches Colorectal Cancer Study with Fast Track Designation.

Oncolytics Biotech has launched a randomized study to confirm previous efficacy in colorectal cancer. The study will compare a pelareorep-based treatment regimen to the current standard of care in second-line RAS-mutated, microsatellite-stable metastatic colorectal cancer patients. Preliminary data is expected by the end of 2026. The pelareorep-based regimen has been granted Fast Track Designation for this indication.